Funders · Entity Annotation Prototype (beta)

2articles mentioning funders

3funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Bristol-Myers Squibb ×

Bristol-Myers Squibb

This funder is selected. Its supporting articles are shown below.

Bristol-Myers Squibb2

Articles mentioning Bristol-Myers Squibb

2 articles · page 1 of 1

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

jitc · abstract · 2025-11-07 · 2 matching annotations

81.3%

NIH-NCI Bristol-Myers Squibb NCI melanoma nivolumab relatlimab

…tically reading the manuscript. This study was supported by the NIH-NCI (P50 SPORE CA254865 to J.M.K., D.A.A.V., T.C.B.) and Bristol-My…

511 Specific TCR clones associated with better pathological response for early stage NSCLC patients treated with neoadjuvant immunotherapy: results from CTONG1804

jitc · abstract · 2025-11-04 · 1 matching annotations

94.6%

Bristol-Myers Squibb neoadjuvant immunotherapy nivolumab EGFR-mutant NSCLC chemotherapy CTONG1104